Treatment of Complications to Diabetic Autonomic Neuropathy With Vagus Nerve Stimulation (DAN-VNS)

Aalborg University Hospital

Status

Completed

Conditions

Diabetes Mellitus

Gastrointestinal Dysfunction

Treatments

Device: Sham vagus nerve stimulation

Device: Non-invasive transcutaneous vagus nerve stimulation

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04143269

N-20190020 (Other Identifier)

CIV-19-07-029105 (Other Identifier)

DAN-VNS

Details and patient eligibility

About

The purpose of the DAN-VNS study is to investigate the effects of non-invasive vagal nerve stimulation on gastrointestinal symptoms such as nausea, vomiting, bloating, and diarrhea in people with diabetes.

Full description

The study is a randomized, double-blinded, sham-controlled, parallel group clinical trial, which will include participants with diabetes and gastrointestinal (GI) problems. These problems may be manifestations of diabetic autonomic neuropathy.

Participants are randomised to received either active non-invasive transcutaneous vagal nerve stimulation (tVNS) or inactive sham stimulation. The study period is divided in two phases. The first phase investigates the effects of short-term, high-intensity tVNS treatment on GI symptoms. The second phase investigates the effects of long-term, middle-intensity tVNS treatment. The primary outcome of both phases is subjective patient evaluation of GI symptoms by the use of validated questionnaires.

A third phase, conducted only on participants, who proved to be responsive to tVNS treatment, will investigate the acute endocrine and metabolic response to short-term tVNS in a randomised cross-over design.

Lastly, healthy volunteers will be included in a cross-sectional, descriptive study in order to provide a comparable baseline dataset.

Enrollment

120 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
Verified diagnosis of diabetes for a minimum of 1 year and with stable medication
CAN-score ≥ 1 (measured by the Vagus device (Medicus Engineering, Aarhus, Denmark) OR COMPASS-31 score of ≥ 16 OR electrochemical resistance <50µS (hands) and <70µS (feet) assessed with the SUDOSCAN device
Weighted composite score of Gastroparesis Cardinal Symptom Index (GCSI) and Gastrointestinal Symptom Rating Scale (GSRS) ≥ 2.3
Ability to read and understand Danish
Personally signed and dated informed consent documents
Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures

Exclusion criteria

Significant GI diseases not related to diabetes
Significant cardiovascular diseases
GI surgery within 3 months prior to study inclusion
Swallowing disorders
Blood pressure < 100/60 or > 160/105
Clinically significant bradycardia or tachycardia
Implanted portable electro-mechanical medical devices including pacemaker, defibrillator, cochlear implant, and infusion pump
Previous surgery of the vagus nerve
Active laser treatment for proliferative retinopathy
Contraindications for MRI
Any clinical abnormalities, that in the opinion of the investigator may increase the risk associated with trial participation or may interfere with the interpretation of the trial results
Pregnancy or intention to become pregnant or father a child during the course of the study
Participation in other clinical trials less than three months prior to inclusion, unless such a participation is judged to have no influence on the recordings